SELECT PUBLICATIONS
Allegra CJ et al. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. Proc ASCO 2008;Abstract 4006.
Balneaves LG et al. Patient decision-making about complementary and alternative medicine in cancer management: Context and process. Curr Oncol 2008;15(Suppl 2):s94-100. Abstract
Berry SR et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. ASCO 2008;Abstract 4025.
Cunningham D et al Efficacy and safety of surgery with curative intent in patients treated with first-line bevacizumab for mCRC: First BEAT. Proc ASCO 2008;Abstract 445.
Decker GM. The marriage of conventional cancer treatments and alternative cancer therapies. Nurs Clin North Am 2008 Jun;43(2):221-41; v-vi. Abstract
Flynn PJ et al. Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS). Proc ASCO 2008;Abstract 4104.
Giantonio BJ et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44. Abstract
Gobel BH. Nursing considerations of bevacizumab use in multiple tumor types. Oncol Nurs Forum 2007;34(3):693-701. Abstract
Godino C et al. Nursing education as an intervention to decrease fatigue perception in oncology patients. Eur J Oncol Nurs 2006;10(2):150-5. Abstract
Hochster HS et al.
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008;26(21):3523-9.
Abstract
Klinger M et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer metastases: Effect of bevacizumab. Proc ASCO 2008;Abstract 4082.
Leis A, Millard J. Complementary and alternative medicine (CAM) and supportive care in cancer: A synopsis of research perspectives and contributions by an interdisciplinary team. Support Care Cancer. 2007;15(8):909-12. Abstract
Lemmens L et al. Managing patients with metastatic colorectal cancer on bevacizumab. Br J Nurs 2008;17(15):944-9. Abstract
Mitchell SA et al. Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11(1):99-113. Abstract
Mitchell T. The social and emotional toll of chemotherapy — Patients' perspectives. Eur J Cancer Care (Engl) 2007;16(1):39-47. Abstract
Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008;371(9617):1007-16. Abstract
Purdie DM et al. The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS). Proc ASCO 2008;Abstract 4103.
Saltz LB et al.
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26(12):2013-9.
Abstract
Saxe GA et al. Disclosure to physicians of CAM use by breast cancer patients: Findings from the Women's Healthy Eating and Living Study. Integr Cancer Ther 2008;7(3):122-9. Abstract
Seely D, Oneschuk D. Interactions of natural health products with biomedical cancer treatments? Curr Oncol 2008;15(Suppl 2):s81-6. Abstract
Sugrue MM et al. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS). Proc ASCO 2008;Abstract 4105.
Verhoef MJ et al. Talking to cancer patients about complementary therapies: Is it the physician's responsibility. Curr Oncol 2008;15(Suppl 2):s88-93. Abstract
Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 2007;23(3):162-73. Abstract
